Compare KGS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | ERAS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | 1300 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.3B |
| IPO Year | 2023 | 2021 |
| Metric | KGS | ERAS |
|---|---|---|
| Price | $58.63 | $14.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $57.17 | $14.25 |
| AVG Volume (30 Days) | 1.6M | ★ 4.1M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 58.93 | 36.23 |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.30 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | $77.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.55 | $1.75 |
| 52 Week High | $77.68 | $24.28 |
| Indicator | KGS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 33.44 |
| Support Level | $54.65 | $14.00 |
| Resistance Level | $65.80 | $15.03 |
| Average True Range (ATR) | 2.42 | 1.06 |
| MACD | -0.21 | -0.15 |
| Stochastic Oscillator | 40.08 | 11.79 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. The company manages its business through two operating segments: Contract Services and Other Services. Contract Services consists of operating company-owned and customer-owned compression, gas treating, and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings. Maximum revenue for the company is generated from its Contract Services segment.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.